Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsFRA:CN2 93 Quick Ratio is 6.84 as of Mar. 2026, which is 5% above its 10-year median of 6.53. GuruFocus rates FRA:CN2 with a GF Score™ of 93/100 and a GF Value™ of €21.47 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,411 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 68.67% on this metric.
Catalyst Pharmaceuticals has a quick ratio of 6.84. It generally indicates good short-term financial strength.
The historical rank and industry rank for Catalyst Pharmaceuticals's Quick Ratio or its related term are showing as below:
FRA:CN2'
s Quick Ratio Range Over the Past 10 Years
Min: 2.68 Med: 6.53 Max: 28.9
Current: 6.84
During the past 13 years, Catalyst Pharmaceuticals's highest Quick Ratio was 28.90. The lowest was 2.68. And the median was 6.53.
FRA:CN2's Quick Ratio is ranked better than 68.67% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs FRA:CN2: 6.84
Catalyst Pharmaceuticals (FRA:CN2) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Catalyst Pharmaceuticals Quick Ratio Related Terms
Catalyst Pharmaceuticals Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CN2 vs CRNX, NAMS, RCUS: Quick Ratio Comparison
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Catalyst Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (FRA:CN2) has a Quick Ratio of 6.84 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Catalyst Pharmaceuticals and its competitors. This is near median its historical median of 6.53. Over the past decade, Catalyst Pharmaceuticals' Quick Ratio has ranged from 2.68 to 28.90. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #442 out of 1411 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Catalyst Pharmaceuticals' Quick Ratio too high?
Catalyst Pharmaceuticals' current Quick Ratio of 6.84 is near median its 10-year median of 6.53. Over the past 10 years, this metric has ranged from a low of 2.68 to a high of 28.90. The Biotechnology industry median Quick Ratio is 3.59. Catalyst Pharmaceuticals' value of 6.84 is 90.5% above this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #442 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' Quick Ratio compare to CRNX and NAMS?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #442 out of 1411 companies for Quick Ratio. This puts Catalyst Pharmaceuticals in the upper half of its industry. The industry median Quick Ratio is 3.59. Catalyst Pharmaceuticals' value of 6.84 is 90.5% above this benchmark. Historically, Catalyst Pharmaceuticals' own Quick Ratio has ranged from 2.68 to 28.90 over the past decade. While the company's 10-year median is 6.53 vs. the industry median of 3.59, Catalyst Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current Quick Ratio of 6.84 is 90.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Catalyst Pharmaceuticals and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current Quick Ratio is 6.84, which is near median its own 10-year median of 6.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (FRA:CN2) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.47, compared to a current price of €27.30 — trading 27.2% above its estimated fair value. The current Quick Ratio is 6.84, which is near median its 10-year median of 6.53 and 90.5% above the Biotechnology industry median of 3.59. Catalyst Pharmaceuticals' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Catalyst Pharmaceuticals (FRA:CN2), the current Quick Ratio is 6.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (FRA:CN2) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of €27.30 is trading 27.2% above its estimated GF Value™ of €21.47.
GuruFocus considers Catalyst Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:CN2:
Quick Ratio: 6.84 (near median its 10-year median of 6.53)
GF Value™: €21.47 vs. price of €27.30 (27.2% above fair value)
Industry Position: 90.5% above the Biotechnology median (#442 of 1411)
No single metric tells the full story. See the FRA:CN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
93GF Score
Get the complete analysis for FRA:CN2
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CN2 has been successfully added to your 
